Fabio Broccatelli

Fabio Broccatelli

Auto-generated profile, based on publicly available information

Fabio Broccatelli

Bristol-Myers Squibb Company, San Diego, California 92121, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FLFranco Lombardo
Franco Lombardo
PDPrashant V. Desai
Prashant V. Desai
RARieko Arimoto
Rieko Arimoto
KDKelly E. Desino
Kelly E. Desino
HFHolger Fischer
Holger Fischer
FBFabio Broccatelli
Fabio Broccatelli

11 November 2016 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
FBF. Broccatelli
F. Broccatelli
LSL. Salphati
L. Salphati
EPE. Plise
E. Plise
JCJ. Cheong
J. Cheong
AGA. Gobbi
A. Gobbi
IAI. Aliagas
I. Aliagas

19 April 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
FBFabio Broccatelli
Fabio Broccatelli
IAIgnacio Aliagas
Ignacio Aliagas
HZHao Zheng
Hao Zheng

30 May 2022 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
RJRobert S. Jones
Robert S. Jones
CLChristian Leung
Christian Leung
JCJae H. Chang
Jae H. Chang
SBSuzanne Brown
Suzanne Brown
NLNing Liu
Ning Liu
FBFabio Broccatelli
Fabio Broccatelli
The utilization of in vitro data to predict drug pharmacokinetics (PK) in vivo has been a consistent practice in early drug discovery for decades. However, its success is hampered by mispredictions attributed to uncharacterized biological phenomena/experimental artifacts. Predicted drug clearance (CL) from experimental data (i.e. hepatocyte intrinsic clearance: CLint, fraction unbound in plasma: fu,p) is often systematically underpredicted using the well-stirred model (WSM). The objective of this study was to evaluate using empirical scalars in the WSM to correct for CL mispredictions. Drugs (N=28) were used to generate numerical scalars on CLint (α), and fu,p (β) to minimize the error (AAFE) for CL predictions. These scalars were validated using an additional dataset (N=28 drugs) and applied to a non-redundant AstraZeneca (AZ) dataset available in the literature (N=117 drugs) for a total of 173 compounds. CL predictions using the WSM were improved for most compounds using an α value of 3.66 (~64%<2-fold) compared to no scaling (~46%<2-fold). Similarly, using a β value of 0.55 or combination of α and β scalars (values of 1.74 and 0.66, respectively) resulted in a similar improvement in predictions (~64%<2-fold and ~65%<2-fold, respectively). For highly bound compounds (fu,p{less than or equal to}0.01), AAFE was substantially reduced across all scaling methods. Using the β scalar alone or a combination of α and β appeared optimal; and produce larger magnitude corrections for highly-bound compounds. Some drugs are still disproportionally mispredicted, however the improvements in prediction error and simplicity of applying these scalars suggests its utility for early-stage CL predictions. Significance Statement In early drug discovery, prediction of human clearance using in vitro experimental data plays an essential role in triaging compounds prior to in vivo studies. These predictions have been systematically underestimated. Here we introduce empirical scalars calibrated on the extent of plasma protein binding that appear to improve clearance prediction across multiple datasets. This approach can be used in early phases of drug discovery prior to the availability of pre-clinical data for early quantitative predictions of human clearance.

8 March 2018 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
RCRosa Chan
Rosa Chan
TBTom De Bruyn
Tom De Bruyn
MWMatthew Wright
Matthew Wright
FBFabio Broccatelli
Fabio Broccatelli

8 August 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PKPonien kou
Ponien kou
ELElizabeth Levy
Elizabeth Levy
ANAn Duc Nguyen
An Duc Nguyen
DZDonglu Zhang
Donglu Zhang
SCShu Chen
Shu Chen
VSvijay sethuraman
vijay sethuraman
Proteolysis-Targeting Chimeras (PROTACs) are a promising new technology in drug development. They have rapidly evolved in recent years, with several of them in clinical trials. While most of these advances have been associated with monovalent protein degraders, bivalent PROTACs have also entered clinical trials, although progression to market has been limited. One of the reasons is the complex physicochemical properties of the heterobifunctional PROTACs. A promising strategy to improve pharmacokinetics of highly lipophilic compounds, such as PROTACs, is encapsulation in liposome systems. Here we describe liposome systems for intravenous administration to enhance the PK properties of two bivalent PROTAC molecules, by reducing clearance and increasing systemic coverage. We developed and characterized a PROTAC-in-cyclodextrin liposome system where the drug was retained in the liposome core. In PK studies at 1 mg/kg for GNE-01 the PROTAC-in-cyclodextrin liposome, compared to the solution formulation, showed a 80- and a 380-fold enhancement in AUC for mouse and rat studies, respectively. We further investigated the same PROTAC-in-cyclodextrin liposome system with the second PROTAC (GNE-02), where we monitored both lipid and drug concentrations in vivo. Similarly, in a mouse PK study of GEN-02, the PROTAC-in-cyclodextrin liposome system exhibited enhancement in plasma concentration of a 23× increase over the conventional solution formulation. Importantly, the lipid CL correlated with the drug CL. Additionally, we investigated a conventional liposome approach for GNE-02, where the PROTAC resides in the lipid bilayer. Here, a 5× increase in AUC was observed, compared to the conventional solution formulation, and the drug CL was faster than the lipid CL. These results indicate that the different liposome systems can be tailored to translate across multiple PROTAC systems to modulate and improve plasma concentrations. Optimization of the liposomes could further improve tumor concentration and improve the overall therapeutic index (TI). This delivery technology may be well suited to bring novel protein targeted PROTACs into clinics.